Research Article
Dual-Task Interference: The Effects of Verbal Cognitive Tasks on Upright Postural Stability in Parkinson's Disease
Table 1
Clinical features of individuals with Parkinson's disease.
| Subject | Gender | Age (y) | Duration of Illness (y) | Hoehn & Yahr | UPDRS III | Medication | Dosage total/day |
| PD1 | Female | 67 | 2 | 1.5 | 19 | None | — | PD2 | Male | 78 | 8 | 2.5 | 36 | Levodopa/Carbidopa | 650 mg | Pramipexole | 2.25 mg | PD3 | Male | 69 | 3 | 2.0 | 23 | Levodopa/Carbidopa | 350 mg | PD4 | Male | 58 | 4 | 2.5 | 24 | Pramipexole | 1.5 mg | PD5 | Female | 50 | 9 | 2.5 | 20 | Levodopa/Carbidopa | 400 mg | Ropinirole | 9.5 mg | PD6 | Male | 60 | 2 | 1.5 | 17 | Pramipexole | 1.5 mg | PD7 | Female | 76 | 3 | 2.5 | 26 | Levodopa/Carbidopa CR | 400 mg | PD8 | Male | 59 | 5 | 2.0 | 26 | Levodopa/Carbidopa | 300 mg | Pramipexole | 3.0 mg | PD9 | Male | 49 | 4 | 2.0 | 28 | Ropinirole | 12.0 mg | PD10 | Female | 67 | 8 | 2.0 | 21 | Levodopa/Carbidopa CR | 200 mg | Levodopa/Carbidopa | 200 mg | PD11 | Male | 67 | 6 | 2.5 | 21 | Levodopa/Carbidopa | 1000 mg | Pramipexole | 2.0 mg | PD12 | Male | 68 | 5 | 2.0 | 28 | Levodopa/Carbidopa | 400 mg | Pramipexole | 0.75 mg | Entacapone | 800 mg | | Mean | 64.00 | 4.92 | 2.13 | 24.08 | — | — | | (SD) | (9.08) | (2.39) | (0.38) | (5.16) | | |
|
|